FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies

Trastuzumab deruxtecan and elacestrant represent important new treatment options.

Related Keywords

Texas ,United States ,Mirat Shah ,Preeti Narayan ,Daiichi Sankyo ,Astrazeneca ,Office Of Hematology ,Menarini Group ,Antonio Breast Cancer Symposium ,Oncology Products ,Drug Evaluation ,